Why is this study important?  

  • Proof of concept of new technique for direct reduction in mitral valve annular area. 
  • Identified a potential new adjunctive therapy to current TEER procedures. 

What question was this study supposed to answer? 

  • Previous attempts at annular reduction using the coronary sinus have been disappointing. 
  • This study demonstrated the technical feasibility of intramyocardial device delivery. 

What did the study show? 

  • Procedural success in a small group (n=19) of HFpEF and HFrEF patients with persistent MR after TEER. 
  • The ability to evaluate the procedural success and potential complications and stop the procedure without complications. 
  • Improvement in both physiologic parameters and clinical functional status. 


All authors: Steven R. Bailey, MD, MSCAI

Other Specialist Resources for Structural Heart Disease

Including recently published studies, coverage of late-breaking science, updates from clinical trials and registries, and complex case presentations. 

Clinical Interest Article

ADAPT-TAVR Trial—Coverage of ACC.22

Routine Use of Edoxaban Post-TAVR in Patients Without an Indication for Anticoagulation Does Not Significantly Reduce Valve Thrombo...